Freedom Capital analyst Ilya Zubkov upgraded Eli Lilly (LLY) to Buy from Hold with a price target of $1,200, up from $1,050, following what the firm describes as “another quarter that beat even the high-end of revenue and EPS estimates,” driven by record GLP-1 sales. Given Lilly’s “dominant position” in the GLP-1 market and the long-term potential from an oral drug launch, the firm raised its rating.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Lilly Advances Eloralintide Into Phase 3, Expanding Its Obesity Drug Ambitions
- Eli Lilly’s Solbinsiran Trial Advances in High-Risk Cholesterol Market
- Lilly’s ENLIGHTEN-4 Trial Targets Knee Osteoarthritis Pain in Overweight Patients
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Midday Fly By: Transocean to buy Valaris, Kyndryl sinks after CFO exit